BSX

SEC source: 0001225208-26-007620 · doc4.xml · derivative · entry 3

O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,516

Underlying: Common Stock · 1,171 shares

Expires 2029-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on September 2, 2026, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on September 2, 2026, the first anniversary of the date of grant.

SEC source: 0001225208-26-007620 · doc4.xml · nonDerivative · entry 2

O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,892

SEC source: 0001225208-26-007620 · doc4.xml · nonDerivative · entry 1

O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · balance_after: Includes shares acquired under the Boston Scientific Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-26-007337 · doc4.xml · nonDerivative · entry 1

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,784

SEC source: 0001225208-26-007084 · doc4.xml · nonDerivative · entry 1

Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Indirect · By 401(k)

Disclosed balance after: 2,930

F1 · kind: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

SEC source: 0001225208-26-007062 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By 401(k)

Disclosed balance after: 9,908

F1 · kind: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

SEC source: 0001225208-26-007031 · doc4.xml · nonDerivative · entry 1

Habiger David C · CIK 0001326409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,160

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.21 to $47.98, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-006951 · doc4.xml · nonDerivative · entry 2

Habiger David C · CIK 0001326409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,060

F2 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-006951 · doc4.xml · nonDerivative · entry 1

Habiger David C · CIK 0001326409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,920

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.055 to $48.070, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-006950 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By 401(k)

Disclosed balance after: 22,119

F2 · kind: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

SEC source: 0001225208-26-006950 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,590,024

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-006882 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,359

SEC source: 0001225208-26-006881 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Indirect · By 401(k)

Disclosed balance after: 64,198

F1 · kind: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

F2 · balance_after: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

SEC source: 0001225208-26-006362 · doc4.xml · derivative · entry 3

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,263

Underlying: Common Stock · 2,087 shares

Expires 2029-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2026, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2026, the first anniversary of the date of grant.

SEC source: 0001225208-26-006362 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,063

SEC source: 0001225208-26-006362 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-26-005670 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · kind: This transaction involved a gift of securities by the reporting person to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.

SEC source: 0001225208-26-005548 · doc4.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,770

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.49 to $56.5009, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-005547 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,359

SEC source: 0001225208-26-005546 · doc4.xml · nonDerivative · entry 2

Habiger David C · CIK 0001326409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,878

F2 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $55.85 to $56.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-005546 · doc4.xml · nonDerivative · entry 1

Habiger David C · CIK 0001326409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,628

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.93 to $56.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-005115 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,934

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005114 · doc4.xml · nonDerivative · entry 1

WICHMANN DAVID S · CIK 0001268489 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,382

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005113 · doc4.xml · derivative · entry 3

Weber Christophe Pierre · CIK 0002011270 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,660

Underlying: Common Stock · 2,660 shares

Expires not disclosed

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

F4 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

F4 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005113 · doc4.xml · nonDerivative · entry 2

Weber Christophe Pierre · CIK 0002011270 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,786

F2 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Reflects a value of $64,500 (representing 30% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005113 · doc4.xml · nonDerivative · entry 1

Weber Christophe Pierre · CIK 0002011270 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,646

F1 · kind: Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $100,000 (representing 80% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-005112 · doc4.xml · derivative · entry 2

Smith Cathy R · CIK 0001322028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,888

Underlying: Common Stock · 2,209 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.

F4 · derivative.exercise_date: Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.

F4 · derivative.expiration_date: Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-005112 · doc4.xml · derivative · entry 1

Smith Cathy R · CIK 0001322028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,679

Underlying: Common Stock · 3,800 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-26-005111 · doc4.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,998

Underlying: Common Stock · 1,281 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.exercise_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.expiration_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-005111 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,717

Underlying: Common Stock · 3,800 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-26-005110 · doc4.xml · nonDerivative · entry 2

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,744

F2 · kind: Grant of restricted stock in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-005110 · doc4.xml · nonDerivative · entry 1

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,463

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005109 · doc4.xml · nonDerivative · entry 1

Mega Jessica L · CIK 0001793582 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,035

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005108 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,779

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-005107 · doc4.xml · nonDerivative · entry 1

Habiger David C · CIK 0001326409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,428

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-004897 · doc4.xml · derivative · entry 3

O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,802 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-26-004897 · doc4.xml · nonDerivative · entry 2

O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,024

SEC source: 0001225208-26-004897 · doc4.xml · nonDerivative · entry 1

O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-26-004896 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,102 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-26-004896 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,887

SEC source: 0001225208-26-004896 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,894

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-26-003180 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,917

Underlying: Common Stock · 24 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

F2 · derivative.expiration_date: Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-003179 · doc4.xml · nonDerivative · entry 1

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,663

F1 · shares: Restricted stock granted in lieu of 50% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $1,845.25, divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-003178 · doc4.xml · nonDerivative · entry 2

Weber Christophe Pierre · CIK 0002011270 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 879

F2 · price: Grant of restricted stock in lieu of 100% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-003178 · doc4.xml · nonDerivative · entry 1

Weber Christophe Pierre · CIK 0002011270 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 556

F1 · price: Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-26-003177 · doc4.xml · derivative · entry 2

Smith Cathy R · CIK 0001322028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 879

Underlying: Common Stock · 323 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-26-003177 · doc4.xml · derivative · entry 1

Smith Cathy R · CIK 0001322028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 556

Underlying: Common Stock · 556 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-26-003014 · doc4.xml · derivative · entry 3

Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,676

Underlying: Common Stock · 838 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on March 1, 2025, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on March 1, 2025, the first anniversary of the date of grant.

SEC source: 0001225208-26-003014 · doc4.xml · nonDerivative · entry 2

Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,859

SEC source: 0001225208-26-003014 · doc4.xml · nonDerivative · entry 1

Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.